Copper-64 Based PET-Radiopharmaceuticals: Ways to Clinical Translational

IF 4.6 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Seminars in nuclear medicine Pub Date : 2024-11-01 DOI:10.1053/j.semnuclmed.2024.10.002

Nan Yang PhD , Xiao-yi Guo PhD , Jin Ding PhD, Feng Wang PhD, Te-li Liu PhD, Hua Zhu MD, PhD , Zhi Yang MD, PhD

{"title":"Copper-64 Based PET-Radiopharmaceuticals: Ways to Clinical Translational","authors":"Nan Yang PhD , Xiao-yi Guo PhD , Jin Ding PhD, Feng Wang PhD, Te-li Liu PhD, Hua Zhu MD, PhD , Zhi Yang MD, PhD","doi":"10.1053/j.semnuclmed.2024.10.002","DOIUrl":null,"url":null,"abstract":"<div><div>Positron emission tomography (PET) as an advanced noninvasive imaging technique, provides unprecedented insights into the study of physiological and biochemical processes in vivo. Copper-64 (<sup>64</sup>Cu) has a ideal half-life of 12.7 hours, with β+ and β-dual decay modes and abundant coordination chemistry, enabling the development of a wide variety of radiopharmaceuticals for PET imaging and radionuclide therapy.This review provides a comprehensive overview of the latest advances in Copper-64 (<sup>64</sup>Cu)-based PET radionuclides, covering their production, radiolabeling strategies, and clinical applications. It highlights the role of <sup>64</sup>Cu-PET in enhancing diagnostic accuracy and therapeutic outcomes across various tumor types. Additionally, future research directions and the evolving clinical applications of <sup>64</sup>Cu-based radiopharmaceuticals are discussed, offering insights into their potential impact on clinical practice.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 6","pages":"Pages 792-800"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299824000862","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Positron emission tomography (PET) as an advanced noninvasive imaging technique, provides unprecedented insights into the study of physiological and biochemical processes in vivo. Copper-64 (⁶⁴Cu) has a ideal half-life of 12.7 hours, with β+ and β-dual decay modes and abundant coordination chemistry, enabling the development of a wide variety of radiopharmaceuticals for PET imaging and radionuclide therapy.This review provides a comprehensive overview of the latest advances in Copper-64 (⁶⁴Cu)-based PET radionuclides, covering their production, radiolabeling strategies, and clinical applications. It highlights the role of ⁶⁴Cu-PET in enhancing diagnostic accuracy and therapeutic outcomes across various tumor types. Additionally, future research directions and the evolving clinical applications of ⁶⁴Cu-based radiopharmaceuticals are discussed, offering insights into their potential impact on clinical practice.

查看原文本刊更多论文

基于铜-64 的 PET 放射药物：临床转化的途径

正电子发射断层扫描（PET）作为一种先进的无创成像技术，为研究体内生理和生化过程提供了前所未有的洞察力。铜-64（64Cu）的理想半衰期为 12.7 小时，具有 β+ 和 β 双衰变模式和丰富的配位化学性质，能够开发出多种用于 PET 成像和放射性核素治疗的放射性药物。本综述全面概述了以铜-64（64Cu）为基础的 PET 放射性核素的最新进展，包括其生产、放射性标记策略和临床应用。它强调了 64Cu-PET 在提高各种肿瘤类型的诊断准确性和治疗效果方面的作用。此外，还讨论了 64Cu 基放射性药物的未来研究方向和不断发展的临床应用，深入探讨了它们对临床实践的潜在影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.